148 related articles for article (PubMed ID: 34882663)
1. Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice - one center study.
Cecha P; Chromik A; Piotrowska I; Zabojszcz M; Dolecka-Ślusarczyk M; Siudak Z
Folia Med Cracov; 2021 Sep; 61(3):43-54. PubMed ID: 34882663
[TBL] [Abstract][Full Text] [Related]
2. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
[TBL] [Abstract][Full Text] [Related]
4. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
[TBL] [Abstract][Full Text] [Related]
5. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
[TBL] [Abstract][Full Text] [Related]
7. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
[TBL] [Abstract][Full Text] [Related]
8. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
9. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey.
Koskinas KC; Catapano AL; Baigent C; Tokgozoglu L; Mach F
Eur J Prev Cardiol; 2022 Feb; 28(18):2030-2037. PubMed ID: 33580792
[TBL] [Abstract][Full Text] [Related]
10. New concepts in the management of dyslipidaemiaa.
Gencer B; Rodondi N; Mach F
Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
[TBL] [Abstract][Full Text] [Related]
11. LDL as a therapeutic target.
Díaz Rodríguez Á; Mantilla Morató T
Clin Investig Arterioscler; 2022; 34(5):271-284. PubMed ID: 35339296
[TBL] [Abstract][Full Text] [Related]
12. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
[TBL] [Abstract][Full Text] [Related]
13. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
14. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
15. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
; Reiner Z; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D;
Eur Heart J; 2011 Jul; 32(14):1769-818. PubMed ID: 21712404
[TBL] [Abstract][Full Text] [Related]
16. [ECS guidelines 2016 - dyslipidaemias].
Sinning D; Landmesser U
Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
[TBL] [Abstract][Full Text] [Related]
17. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
18. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
19. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]